Oxidation of cyclophosphamide to 4-hydroxycyclophosphamide and deschloroethylcyclophosphamide in human liver microsomes

Cancer Research

Volumn 57, Issue 19, 1997, Pages 4229-4235

  Ren, Song ^a   Yang, Ji Sun ^a,b   Kalhorn, Thomas F ^a   Slattery, John T ^a,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Korea Food and Drug Administration   (South Korea)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 HYDROXYCYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE; CYCLOPHOSPHAMIDE DERIVATIVE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; ISOENZYME; ORPHENADRINE; SULFAPHENAZOLE; TROLEANDOMYCIN;

ARTICLE; CONTROLLED STUDY; DRUG DETERMINATION; DRUG OXIDATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER MICROSOME; LIVER MICROSOME METABOLISM; PRIORITY JOURNAL;

ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; CYCLOPHOSPHAMIDE; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; ISOENZYMES; KINETICS; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; ORPHENADRINE; OXIDATION-REDUCTION; PRODRUGS; RECOMBINANT FUSION PROTEINS; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; TROLEANDOMYCIN;

EID: 0030799414     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Sladek, N. E. Metabolism and pharmacokinetics of cyclophosphamide and related oxazaphosphorines. In: G. Powis (ed.), Anticancer Drugs: Reactive Metabolism and Drug Interactions, pp. 79-156. New York: Pergamon Press, Ltd., 1994.
2. Colvin, M., Padgett, C. A., and Fenselau, C. A biologically active metabolite of cyclophosphamide. Cancer Res., 33: 915-918, 1973.
3. Connors, T. A., Cox, P. J., Farmer, P. B., Foster, A. B., and Jarman, M. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and ifosphamide. Biochem. Pharmacol., 23: 115-129, 1974.
4. Struck, R. F., Kirk, M. C., Witt, M. H., and Laster, W. R., Jr. Isolation and mass spectral identification of blood metabolites of cyclophosphamide: evidence for phosphoramide mustard as the biologically active metabolite. Biomed. Mass Spectrom., 2: 46-52, 1975.
5. Ayash, L. J., Wright, J. E., Tretyakov, O., Gonin, R., Elias, A., Wheeler, C., Eder, J. P., Rosowsky, A., Antman, K., and Frei, E. Cyclophosphamide pharmacokinetics: correlation with cardiac toxicity and tumor response. J. Clin. Oncol., 10: 995-1000, 1992.
6. Slattery, J. T., Kalhorn, T. F., McDonald, G. B., Lambert, K., Buckner, C. D., Bensinger, W. I., Anasetti, C., and Appelbaum, F. R. Conditioning regimen-dependent disposition of cyclophosphamide and hydroxycyclophosphamide in human marrow transplantation patients. J. Clin. Oncol., 14: 1484-1494, 1996.
7. Brock, N., Gross, R., Hohorst, H. J., Klein, H. O., and Schneider, B. Activation of cyclophosphamide in man and animals. Cancer (Phila.), 27: 1512-1529, 1971.
8. Ruzicka, J. A., and Ruenitz, P. C. Cytochrome P-450-mediated N-dechloroethylation of cyclophosphamide and ifosphamide in the rat. Drug Metab. Dispos., 20: 770-772, 1992.
9. Kanekal, S., and Kehrer, J. P. Evidence for peroxidase-mediated metabolism of cyclophosphamide. Drug Metab. Dispos., 21: 37-42, 1993.
10. Kanekal, S., and Kehrer, J. P. Metabolism of cyclophosphamide by lipoxygenases. Drug Metab. Dispos., 22: 74-78, 1994.
11. Chang, T. K. H., Weber, G. F., Crespi, C. L., and Waxman, D. J. Differential activation of cyclophosphamide and ifosphamide by cytochromes P450 2B and 3A in human liver microsomes. Cancer Res., 53: 5629-5637, 1993.
12. Murray, M., Butler, A. M., and Stupans, I. Competitive inhibition of human liver microsomal cytochrome P450 3A-dependent steroid 6 β-hydroxylation activity by cyclophosphamide and ifosphamide in vitro. J. Pharmacol. Exp. Ther., 270: 645-649, 1994.
13. Shimada, T., Yamazaki, H., Mimura, M., Inui, Y., and Guengerich, F. P. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens, and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther., 270: 414-423, 1994.
14. Bohnenstengel, F., Hofman, U., Eichelbaum, M., and Kroemer, H. K. Characterization of the cytochrome P450 involved in side-chain oxidation of cyclophosphamide in humans. Eur. J. Clin. Pharmacol., 51: 279-301, 1996.
15. Takamizawa, A., Matsumoto, S., Iwata, T., Tochino, Y., Katagiri, K., Yamaguchi, K., and Shiratori, O. Studies on cyclophosphamide metabolites and their related compounds. II. Preparation of an active species of cyclophosphamide and related compounds. J. Med. Chem., 18: 376-383, 1975.
16. Friedman, O. M., Boger, E., Grubliauskas, V., and Sommer, H. Synthesis of N-phosphorylated derivatives of nitrogen mustards with latent cytotoxicity. J. Med. Chem., 6: 50-58, 1963.
17. Haining, R. L., Hunter, A. P., Veronese, M. E., Trager, W. F., and Rettie, A. E. Allelic variants of human cytochrome P450 2C9: baculovirus-mediated expression, purification, structural characterization, substrate stereoselectivity, and prochiral selectivity of the wild-type and I359L mutant forms. Arch. Biochem. Biophys., 333: 447-458, 1996.
18. Thummel, K. E., Lee, C. A., Kunze, K. L., Nelson, S. D., and Slattery, J. T. Oxidation of acetaminophen to N-acetyl-p-benzoquinone imine by human CYP3A4. Biochem. Pharmacol., 45: 1563-1569, 1993.
19. Bradford, M. A. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72: 248-254, 1976.
20. Newton, D. J., Wang, R. W., and Lu, A. Y. H. Cytochrome P450 inhibitors evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab. Dispos., 23: 154-158, 1995.
21. Bourrie, M., Meunier, V., Berger, Y., and Fabre, G. Cytochrome P450 isoform inhibitors as a tool for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther., 277: 321-332, 1996.
22. Wrighton, S. A., Stevens, J. C., Becker, G. W., and VandenBranden, M. Isolation and characterization of human liver cytochrome P450 2C19: correlation between 2C19 and (S)-mephenytoin 4′-hydroxylation. Arch. Biochem. Biophys., 500: 240-245, 1993.
23. Huijzer, J. C., Adams, J. D., Jr., Jaw, J. Y., and Yost, G. S. Inhibition of 3-methyl-indole bioactivation by cytochrome P-450 suicide substrates 1-aminobenzotriazole and α-methlbenzylaminobenzotriazole. Drug Metab. Dispos., 17: 37-42, 1989.
24. Colvin, M. The comparative pharmacology of cyclophosphamide and ifosfamide. Semin. Oncol., 9 (Suppl. 1): 2-7, 1982.
25. Roos, P. H., and Mahnke, A. Metabolite complex formation of orphenadrine with cytochrome P450. Involvement of CYP2C11 and CYP3A isozymes. Biochem. Pharmacol., 52: 73-84, 1996.
26. Chen, L., Waxman, D. J., Chen, D., and Kufe, D. W. Sensitization of human breast cancer cells to cyclophosphamide and ifosphamide by transfer of a liver cytochrome P450 gene. Cancer Res., 56: 1331-1340, 1996.
27. Mitra, A. K., Thummel, K. E., Kalhorn, T. F., Kharasch, E. D., Unadkat, J. D., and Slattery, J. T. Inhibition of sulfamethoxazole hydroxylamine formation by fluconazole in human liver microsomes and healthy volunteers. Clin. Pharmacol. Ther., 59: 332-340, 1996.